Sellas Is Not a Platform Story. It Is Two Deaths Away From Finding Out.

The headline says Sellas Life Sciences is building GPS into a lifeline for elderly cancer patients. The reality is that SLS is a 13-person company two deaths away from a binary answer about its only asset.

The stock has surged 362% through late April, hitting a four-year high near $9. The CEO, Angelos Stergiou, has been on a run of bullish appearances, describing GPS as having potential across the "whole gamut" of cancers - up to 20 tumor types. He told investors the company is eyeing FDA talks and positioning for expansion. The narrative is clean enough: a platform drug with broad applicability.